Nanobiotix S.A. (NBTX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $40.14: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Rich valuation.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used... Read more
Sell if holding. Engine safety override at $40.14: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Rich valuation. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Score 5.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 132d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Nanobiotix S.A.
Latest news
- 12 Health Care Stocks Moving In Wednesday's After-Market Session — benzinga May 20, 2026 neutral
- XP Posts Downbeat Q1 Earnings, Joins Akamai Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessi — benzinga May 19, 2026 negative
- Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket — benzinga May 19, 2026 neutral
- Reported Sunday, Nanobiotix CONVERGE Phase 2 Data Shows JNJ-1900 Achieves 100% Disease Control Rate In Stage 3 Inoperabl — benzinga May 18, 2026 positive
- Nanobiotix Nanoprimer Pre-Treatment Demonstrates Reduced Hepatic Toxicity And Improved Systemic Bioavailability For LNP- — benzinga Apr 20, 2026 positive
Generated 2026-05-20T21:56:22Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Unprofitable operations — net margin -73.5%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $40.14: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Rich valuation. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Prior stop was $40.14. Score 5.3/10, moderate confidence.
Take-profit target: $56.00 (+29.7% upside). Prior stop was $40.14. Stop-loss: $40.14.
Target reached (-31.3% upside); Quality below floor (3.5 < 4.0).
Nanobiotix S.A. trades at a P/E of N/A (forward 316.8). TrendMatrix value score: 3.5/10. Verdict: Sell.
12 analysts cover NBTX with a consensus score of 4.3/5. Average price target: $34.
What does Nanobiotix S.A. do?Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the...
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.